

Contents

List of Contributors	xi	VII. Target Validation	68
Foreword	xiii	VIII. Conclusion	68
Preface to the Fourth Edition	xv	References	68
Preface to the Third Edition	xvii		
Preface to the Second Edition	xix		
Preface to the First Edition	xxi		

I

GENERAL ASPECTS OF MEDICINAL CHEMISTRY

1. Medicinal Chemistry: Definitions and Objectives, Drug Activity Phases, Drug Classification Systems

PETER IMMING

I. Definitions and Objectives	3
II. Drug Activity Phases	7
III. Drug Classification Systems	8
References	12

2. Evaluation of the Biological Activity of Compounds: Techniques and Mechanism of Action Studies

IAIN G. DOUGALL AND JOHN UNITT

I. Introduction	15
II. Drug Discovery Approaches and Screening Cascades	16
III. <i>In Vitro</i> Assays	17
IV. <i>Ex Vivo</i> Assays	38
V. <i>In Vivo</i> Assays	39
Acknowledgements	42
References	42

3. Drug Targets, Target Identification, Validation, and Screening

WALTER M.M. VAN DEN BROECK

I. Introduction	45
II. What is a Drug Target?	46
III. The Purpose of Target Identification	47
IV. Target Options and Treatment Options	51
V. Target Deconvolution and Target Discovery	53
VI. Methods for Target Identification and Validation	54

II

LEAD COMPOUND DISCOVERY STRATEGIES

4. Strategies in the Search for New Lead Compounds or Original Working Hypotheses

CAMILLE G. WERMUTH, BRUNO VILLOUTREIX, SERGE GRISONI,
ANNE OLIVIER AND JEAN-PHILIPPE ROCHER

I. Introduction	73
II. First Strategy: Analog Design	74
III. Second Strategy: Systematic Screening	78
IV. Third Strategy: Exploitation of Biological Information	84
V. Fourth Strategy: Planned Research and Rational Approaches	90
VI. Fifth Strategy: Applying Biophysical Technologies and Computational Methods	93
VII. Conclusion	96
References	96

5. Natural Products as Pharmaceuticals and Sources for Lead Structures

DAVID J. NEWMAN, GORDON M. CRAGG AND DAVID G.I. KINGSTON

I. Introduction	102
II. The Importance of Natural Products in Drug Discovery and Development	102
III. The Design of an Effective Natural-Products-Based Approach to Drug Discovery	106
IV. Examples of Natural Products or Analogues as Drugs	116
V. Future Directions in Natural Products as Drugs and Drug Design Templates	128
VI. Summary	130
References	131

6. *In Silico* Screening: Hit Finding from Database Mining

TIAGO RODRIGUES AND GISEBERT SCHNEIDER

I. Introduction	141
II. <i>In Silico</i> Screening	143
III. <i>De Novo</i> Design	150

IV. Conclusions and Future Directions	154
Glossary	156
References	156

7. Fragment-Based Drug Discovery

VENKATA VELVADAPU, BENNETT T. FARMER AND ALLEN B. REITZ

I. Ligand–Protein Interactions: First Principles	162
II. What is Fragment-Based Drug Discovery?	164
III. Creation and Analysis of FBDD Libraries	166
IV. Fragment Screening Methods	167
V. Other Biochemical and Biophysical Methods	171
VI. Fragment Merging/Linking/Growing	172
VII. Fragment Hit Follow-Up, and Pitfalls to Avoid	174
VIII. Zelboraf [®] , First Approved Drug from FBDD	175
IX. Limitations of FBDD	176
X. Trends for the Future	176
References	177

8. Molecular Variations Based on Isosteric Replacements

PAOLA CIAPETTI AND BRUNO GIETHLEN

I. Introduction	181
II. History: Development of the Isosterism Concept	182
III. Currently Encountered Isosteric and Bioisosteric Modifications	186
IV. Scaffold Hopping	220
V. Analysis of the Modifications Resulting from Isosterism	224
VI. Minor Metalloids-Toxic Isosteres	229
References	233

9. Ring Transformations

CHRISTOPHE MORICE AND CAMILLE G. WERMUTH

I. Introduction	243
II. Analogical Approaches	244
III. Disjunctive Approaches	258
IV. Conjunctive Approaches	260
V. Conclusion	263
References	263

10. Macrocycles: Under-Explored and Poorly Exploited Drug Class Despite the Proven Therapeutic Potential

PIERRE RABOISSON

I. Nature as a Source of Macrocycles	267
II. Identification of Macrocyclic Drugs Using Either Phenotypic Screen or Target-Based Approach	268
III. Macrocycles: The Drugs in the Middle Space	270
IV. Effect of the Macrocyclization on Drug-Like Properties	270
V. Interaction of Macrocycles with their Targets	271
VI. Synthesis of Macrocycles & Library Enrichment	274
VII. Conclusion	274
References	274

III

PRIMARY EXPLORATION OF STRUCTURE-ACTIVITY RELATIONSHIPS

11. Conformational Restriction and Steric Hindrance in Medicinal Chemistry

PETER WIPF, ERIN M. SKODA AND ANDRÉ MANN

I. Introduction	279
II. Case Studies	285
III. Summary and Outlook	297
References	297

12. Application Strategies for the Primary Structure–Activity Relationship Exploration

CAMILLE G. WERMUTH, SERGE GRISONI, BRUNO VILLOUTREIX AND JEAN-PHILIPPE ROCHER

I. Introduction	302
II. Preliminary Considerations	302
III. Hit Optimization Strategies	303
IV. Application Rules	312
References	317

13. Substituent Groups

PATRICK BAZZINI AND CAMILLE G. WERMUTH

I. Introduction	319
II. Methyl Groups	320
III. Effects of Unsaturated Groups	331
IV. Effects of Halogenation	338
V. Effects of Hydroxylation	345
VI. Effects of Thiols and Other Sulfur-Containing Groups	346
VII. Acidic Functions	349
VIII. Basic Groups	351
IX. Attachment of Additional Binding Sites	352
References	354

14. The Role of Functional Groups in Drug–Receptor Interactions

LAURENT SCHAEFFER

I. Introduction	359
II. General Principles	360
III. The Importance of the Electrostatic and Steric Match Between Drug and Receptor	360
IV. The Strengths of Functional Group Contributions to Drug–Receptor Interactions	370
V. Cooperative Binding	376
References	377

15. Compound Properties and their Influence on Drug Quality

HONGMING CHEN, OLA ENKVIST AND THIERRY KOGEJ

- I. Introduction
- II. Compound Drug-Likeness Analysis
- III. Compound Promiscuity
- IV. Compound ADMET Properties
- V. Ligand Binding Efficiency Metrics
- VI. Conclusions and Future Outlook
- References

379
380
382
384
386
390
391

19. Multitarget Drugs: Strategies and Challenges for Medicinal Chemists

RICHARD MORPHY AND ZORAN RANKOVIC

- I. Introduction
- II. Strategies for Lead Generation
- III. Main Areas of Focus in Discovery
- IV. Optimization of the Activity Profile and Wider Selectivity
- V. The Physicochemical Challenge
- VI. Summary
- References

379
380
382
384
386
390
391

449
451
453
465
467
469
470

16. Pharmacological Space

ANDREW L. HOPKINS

- I. What is Pharmacological Space?
- II. Chemical Space
- III. Target Space
- IV. Conclusions
- Acknowledgments
- References

395
395
399
405
407
407

20. Selective Optimization of Side Activities (SOSA) in Drug Discovery

TIM JONCKERS

- I. Introduction
- II. Ritonavir: Rejuvenating a Suboptimal Drug
- III. Sildenafil, Side Effects are Not Always Bad
- IV. Nucleotide Prodrugs: Chemical Trojan Horses
- V. Miltefosine
- VI. Aztreonam
- VII. Conclusions
- References

395
395
399
405
407
407

473
474
477
478
481
483
485
485

17. Systems Biology: A New Paradigm for Drug Discovery

HIBA ABI HUSSEIN, ALEXANDRE BORREL, LESLIE REGAD, DELPHINE FLATTERS, ANNE BADEL, COLETTE GENEIX, MICHEL PETITJEAN, ANNE-CLAUDE CAMPROUX AND OLIVIER TABOUREAU

- I. Introduction
- II. Drug-Target Space (off-target)
- III. Systems Biology Space
- IV. Phenotype Space
- V. Examples
- VI. Conclusion
- References

409
413
415
418
418
421
421

IV

SUBSTITUENTS AND FUNCTIONS: QUALITATIVE ASPECTS OF STRUCTURE-ACTIVITY RELATIONSHIPS

18. Optical Isomerism in Drugs

CAMILLE G. WERMUTH

- I. Introduction
- II. Experimental Facts and their Interpretation
- III. Optical Isomerism and Pharmacodynamic Aspects
- IV. Optical Isomerism and Pharmacokinetic Aspects
- V. Practical Considerations
- References

429
430
435
437
439
444

V SPATIAL ORGANIZATION, RECEPTOR MAPPING AND MOLECULAR MODELING

21. Pharmacophore Identification and Pseudo-Receptor Modeling

GERHARD WOLBER AND WOLFGANG SIPPL

- I. Introduction
- II. Methodology
- III. Advanced Approaches
- IV. Application Study: Novel Histamine H₃-Receptor Antagonists
- V. Recent Developments and Outlook
- VI. Conclusions
- References

489
493
497
501
505
507
507

22. Protein Crystallography and Drug Discovery

JEAN-MICHEL RONDEAU AND HERMAN SCHREUDER

- I. Introduction
- II. Historical Background
- III. Basic Principles and Methods of Protein Crystallography
- IV. Applications
- V. Two Selected Examples
- VI. Outlook
- References

511
512
514
527
531
532
533

23. Physiological Aspects Determining the Pharmacokinetic Properties of Drugs

KOEN BOUSSERY, FRANS M. BELPAIRE AND JOHAN VAN DE VOORDE

I. Introduction	539
II. Passage of Drugs Through Biological Barriers	541
III. Drug Absorption	542
IV. Drug Distribution	547
V. Drug Elimination	548
VI. Some Pharmacokinetic Parameters and Terminology	552
VII. Variability in Pharmacokinetics	557
Further Reading	559

24. Biotransformation Reactions and their Enzymes

BERNARD TESTA AND BERND CLEMENT

I. Introduction	561
II. Functionalization Reactions	563
III. Conjugation Reactions	571
IV. Biological Factors Influencing Drug Metabolism	579
V. What is the Relative Significance of These Many Types of Metabolic Reactions?	580
VI. Concluding Remarks	581
References	582

25. Biotransformations Leading to Toxic Metabolites: Chemical Aspects

ANNE-CHRISTINE MACHEREY AND PATRICK M. DANSETTE

I. Historical Background	585
II. Introduction	586
III. Reactions Involved in Bioactivation Processes	587
IV. Examples of Metabolic Conversions Leading to Toxic Metabolites	599
V. Conclusion	608
Acknowledgments	611
References	611

26. Drug Transport Mechanisms and their Impact on the Disposition and Effects of Drugs

JEAN-MICHEL SCHERRMANN

I. Introduction	615
II. Biology and Function of Transporters	616
III. Transporters in Drug Disposition	620
IV. Roles of Transporters in Drug Pharmacokinetics, Pharmacodynamics and Toxicology	624
V. Conclusion	628
Acknowledgments	628
References	628

27. Strategies for Enhancing Oral Bioavailability and Brain Penetration

GERHARD GROSS

I. Introduction	631
-----------------	-----

II. Enhancing Oral Bioavailability	632
III. Enhancing Brain Penetration	645
References	653

28. Designing Prodrugs and Bioprecursors

YONG MI CHOI-SLEDESKI AND CAMILLE G. WERMUTH

I. Introduction	657
II. The Different Kinds of Prodrugs	658
III. Practical Applications of Carrier Prodrugs	661
IV. Unique Approaches to Carrier Prodrug Design	668
V. Bioprecursor Prodrug Examples	686
VI. Discussion	690
VII. Difficulties and Limitations	690
VIII. Conclusion	691
References	692

VI

CHEMICAL MODIFICATIONS INFLUENCING THE PHARMACOKINETIC PROPERTIES

29. Drug Delivery with Organic Solvents or Colloidal Dispersed Systems

BERND U. RIEBESEHL

I. Introduction	699
II. Physicochemical Drug Properties	700
III. Oral Drug Delivery	700
IV. Parenteral Drug Delivery	704
References	720

30. Preparation of Water-Soluble Compounds by Covalent Attachment of Solubilizing Moieties

CAMILLE G. WERMUTH AND DOMINIQUE LESUISSE

I. Introduction	723
II. Solubilization Strategies	724
III. Acidic Solubilizing Chains	726
IV. Basic Solubilizing Chains	734
V. Nonionizable Side Chains	739
VI. Concluding Remarks	741
References	742

31. Improving the Water-Solubility of Compounds by Molecular Modification to Disrupt Crystal Packing

MINORU ISHIKAWA AND YUICHI HASHIMOTO

I. Introduction	747
II. Rationale for Disruption of Crystal Packing as an Alternative Method to Improve Solubility	748
III. Improvement of Solubility by Disrupting Intermolecular Hydrogen Bonds	749

IV. Improvement of Solubility by Disrupting Molecular Planarity	751
V. Improvement of Solubility by Bending the Molecular Structure	760
VI. Advantages of Improving Solubility by Molecular Modification to Weaken Intermolecular Interaction	762
VII. Conclusion	763
References	764

32. Chemical and Physicochemical Approaches to Solve Formulation Problems

HARVEY LIEBERMAN AND N. MURTI VEMURI

I. Introduction	767
II. Stability	767
III. Bioavailability	774
IV. Modifying the Duration of Action	781
V. Manufacturing Issues	782
VI. Adapting to Patient's Needs	783
References	788

33. Discover a Drug Substance, Formulate, and Develop It to a Product

PIERRE deMONTIGNY, DAVID HARRIS, CHRIS HO, FRANZ WEIBERTH, BRUNO GALLI AND BERNARD FALLER

I. Introduction	793
II. The Discovery Phase	794
III. Defining Experimental Formulations, the Creative Phase	796
IV. Preparation for a New Drug-Product Launch	800
V. Conclusion: Drug Discovery and Development in Industry	801
Reference	802

VII

PHARMACEUTICAL AND CHEMICAL MEANS TO SOLUBILITY AND FORMULATION PROBLEMS

34. Drug Nomenclature

RAFFAELLA G. BALOCCO MATTAVELLI, JI-CUI DONG, SOPHIE LASSEUR, A. ROMEO AND SABINE KOPP

I. Introduction	807
II. Trade Names and Nonproprietary Names	807

III. Drug Nomenclature	808
IV. Use and Protection of Nonproprietary Names	819
V. Summary	819
References	820
Annex	820

35. Web Alert: Using the Internet for Medicinal Chemistry

DAVID CAVALLA

I. Introduction	825
II. Blogs	826
III. Wikis	826
IV. Compound Information	827
V. Biological Properties of Compounds	829
VI. Drug Information	831
VII. Physical Chemical Information	832
VIII. Prediction and Calculation of Molecular Properties	832
IX. Chemical Suppliers	834
X. Chemical Synthesis	835
XI. Chemoinformatics Software Programs	836
XII. Chemical Analysis	836
XIII. Chemical Publications	837
XIV. Patent Information	838
XV. Toxicology	839
XVI. Meta-Sites and Technology Service Provider Databases	841
XVII. Conclusion	842

36. Protection of Inventions in Medicinal Chemistry

RICHARD LUTHI AND CHRISTOPHER BRICE

I. Patents and the Medicinal Chemist	843
II. What Kinds of Medical Inventions can be Patented?	845
III. The Basics of Patent Law	846
IV. The Role of the Medicinal Chemist in the Patent Arena	858
V. Patents as a Source of Scientific Information	860
VI. Other Forms of Protection	861
VII. Conclusion	862

Index